Share on StockTwits

InterMune (NASDAQ:ITMN) EVP Sean P. Nolan sold 20,000 shares of the stock on the open market in a transaction dated Friday, June 13th. The stock was sold at an average price of $42.80, for a total transaction of $856,000.00. Following the completion of the sale, the executive vice president now directly owns 65,671 shares in the company, valued at approximately $2,810,719. The transaction was disclosed in a document filed with the SEC, which is available at this link.

InterMune (NASDAQ:ITMN) traded up 1.30% on Friday, hitting $44.46. 2,227,122 shares of the company’s stock traded hands. InterMune has a 52 week low of $9.32 and a 52 week high of $44.59. The stock’s 50-day moving average is $37.31 and its 200-day moving average is $25.58. The company’s market cap is $4.396 billion.

InterMune (NASDAQ:ITMN) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.59) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.62) by $0.03. The company had revenue of $30.30 million for the quarter, compared to the consensus estimate of $28.24 million. During the same quarter in the prior year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was up 188.6% on a year-over-year basis. Analysts expect that InterMune will post $-2.32 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at JMP Securities raised their price target on shares of InterMune from $48.00 to $55.00 in a research note on Thursday. They now have a “market outperform” rating on the stock. Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of InterMune in a research note on Tuesday. They now have a $51.00 price target on the stock, up previously from $45.00. Finally, analysts at William Blair raised their price target on shares of InterMune from $41.00 to $48.00 in a research note on Thursday, May 22nd. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $42.85.

InterMune, Inc (NASDAQ:ITMN), is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.